Royalty Pharma PLC (MEX:RPRX)
MXN 528.5 0 (0%) Market Cap: 243.55 Bil Enterprise Value: 363.97 Bil PE Ratio: 10.43 PB Ratio: 1.73 GF Score: 75/100

Royalty Pharma PLC at Cowen Healthcare Conference (Virtual) Transcript

Mar 02, 2021 / 07:10PM GMT
Stephen Michael Scala
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Good afternoon, and welcome to the Royalty Pharma session at Cowen's 41st Annual Healthcare Conference. We're very pleased to have the company with us this year. Representing the company, Terrance Coyne, who is the Executive Vice President and CFO; and Marshall Urist, who is [Executive] (added by company after the call) Vice President and Co-Head of Research and [Investments] (corrected by company after the call).

We at Cowen view Royalty Pharma as uniquely positioned to enjoy the upside of biopharma with less risk. So we feel this is a very attractive investment opportunity and one that you should take a hard look at.

With that, Terry, I'm going to turn it over to you. I think you have a few slides you'd like to show. And then we'll launch into questions.

Terrance P. Coyne
Royalty Pharma plc - Executive VP & CFO

Great. Thanks, Steve, for having us at the conference today. Before we start the fireside chat, Marshall and I thought it would

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot